Over-the-counter medication availability could augment self-management of male lower urinary tract symptoms

References

• Issa MM, Fenter TC, Black L, et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 Suppl):S83–S89.
   PubMed Web of Science ®Google Scholar
• Fenter TC, Naslund MJ, Shah MB, et al. The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care. 2006;12(4 Suppl):S90–S98.
   PubMed Web of Science ®Google Scholar
• Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–1261.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008;54(3):563–569.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;1(187):116–126.
   Google Scholar
• Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(9 Suppl):S3–S14.
   PubMedGoogle Scholar
• Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008;102(2 Suppl):13–17.
   PubMedGoogle Scholar
• Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43(3):289–297.
   PubMed Web of Science ®Google Scholar
• Platz EA, Joshu CE, Mondul AM, et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol. 2012;188(2):496–501.
   PubMed Web of Science ®Google Scholar
• American Urological Association Guidelines . Management of benign prostatic hyperplasia (BPH) 2010. [2017 Nov 6]. Available from: https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm
   Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–1803.
   PubMed Web of Science ®Google Scholar
• Lieber MM, Jacobson DJ, McGree ME, et al. Intravesical prostatic protrusion in men in Olmsted County, Minnesota. J Urol. 2009;182(6):2819–2824.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Jr FJ F, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 2017;148:1549–1557.
   Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Vignozzi L, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24–31.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee SK, Choo MS, et al. Relationship between metabolic syndrome and lower urinary tract symptoms: Hallym Aging Study. Biomed Res Int. 2015;2015:130917.
   PubMedGoogle Scholar
• Pashootan P, Ploussard G, Cocaul A, et al. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int. 2015;116(1):124–130.
   PubMed Web of Science ®Google Scholar
• Wang JY, Fu YY, Kang DY. The association between metabolic syndrome and characteristics of benign prostatic hyperplasia: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(19):e3243.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen C, Chen Z, et al. Relationship between metabolic syndrome and predictors for clinical benign prostatic hyperplasia progression and International Prostate Symptom Score in patients with moderate to severe lower urinary tract symptoms. Urol J. 2016;13(3):2717–2726.
   PubMed Web of Science ®Google Scholar
• Kim JH, Sun HY, Park SY, et al. Association between obesity and lower urinary tract symptoms: propensity score matching study between healthy controls and obese patients seeking bariatric surgery. Surg Obes Relat Dis. 2016;12(8):1585–1593.
   PubMed Web of Science ®Google Scholar
• Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol. 2014;191(3):715–721.
   PubMed Web of Science ®Google Scholar
• Gacci M, Sebastianelli A, Salvi M, et al. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU Int. 2015;116(2):271–277.
   PubMed Web of Science ®Google Scholar
• Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes. 2007;56(4):1010–1013.
   PubMed Web of Science ®Google Scholar
• Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16(1):101–106.
   PubMed Web of Science ®Google Scholar
• Glass AR, Swerdloff RS, Bray GA, et al. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45(6):1211–1219.
   PubMed Web of Science ®Google Scholar
• Kim MK, Zhao C, Kim SD, et al. Relationship of sex hormones and nocturia in lower urinary tract symptoms induced by benign prostatic hyperplasia. Aging Male. 2012;15(2):90–95.
   PubMed Web of Science ®Google Scholar
• Trifiro MD, Parsons JK, Palazzi‐Churas K, et al. Serum sex hormones and the 20‐year risk of lower urinary tract symptoms in community‐dwelling older men. BJU Int. 2010;105(11):1554–1559.
   PubMed Web of Science ®Google Scholar
• Favilla V, Cimino S, Castelli T, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700–1703.
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Nelson WG, Rifai N, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007;69(4):708–713.
   PubMed Web of Science ®Google Scholar
• Pearl JA, Berhanu D, François N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828–1833.
   PubMed Web of Science ®Google Scholar
• Ventura S, Oliver V, White CW, et al. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163(5):891–907.
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand PK. Nocturia: etiology, diagnosis, and treatment. Neurourol Urodyn. 2008;27(1):34–39.
   PubMed Web of Science ®Google Scholar
• Robinson J. Post-micturition dribble in men: causes and treatment. Nurs Stand. 2008;22(30):43–46.
   PubMedGoogle Scholar
• Kupelian V, Wei JT, O’Leary MP, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166(21):2381–2387.
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.
   PubMedGoogle Scholar
• Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–649.
   PubMed Web of Science ®Google Scholar
• Kim TH, Han DH, Ryu DS, et al. The impact of lower urinary tract symptoms on quality of life, work productivity, depressive symptoms, and sexuality in Korean men aged 40 years and older: a population-based survey. Int Neurourol J. 2015;19(2):120–129.
   PubMed Web of Science ®Google Scholar
• Glover L, Gannon K, McLoughlin J, et al. Men’s experiences of having lower urinary tract symptoms: factors relating to bother. BJU Int. 2004;94(4):563–567.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109.
   PubMed Web of Science ®Google Scholar
• Brown CT, Van Der Meulen J, Mundy AR, et al. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol. 2004;46(2): 254–262. discussion 263.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang X, Hu X, et al. The potential role of a self-management intervention for benign prostate hyperplasia. Urology. 2012;79(6):1385–1388.
   PubMed Web of Science ®Google Scholar
• Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ. 2007;334(7583):25.
   PubMedGoogle Scholar
• Russo GI, Castelli T, Urzi D, et al. Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: a systematic review. Int J Urol. 2015;22(11):982–990.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008;53(6):1228–1235.
   PubMed Web of Science ®Google Scholar
• Washburn RA, Smith KW, Jette AM, et al. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153–162.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Messer K, White M, et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the osteoporotic fractures in men study. Eur Urol. 2011;60(6):1173–1180.
   PubMed Web of Science ®Google Scholar
• Fowke JH, Phillips S, Koyama T, et al. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int. 2013;111(1):122–128.
   PubMed Web of Science ®Google Scholar
• Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45(4):703–708.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74(3):505–508.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562.
   PubMed Web of Science ®Google Scholar
• Gravas S, Oelke M. Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 2010;28(1):9–15.
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM, Wilt TJ. Lower urinary tract symptoms in men. BMJ. 2014;349.
   PubMedGoogle Scholar
• Aoun F, Marcelis Q, Roumeguere T. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update. Res Rep Urol. 2015;7:125–136.
   PubMed Web of Science ®Google Scholar
• Altay B, Erkurt B, Kiremit MC, et al. 180-W XPS GreenLight laser vaporization for benign prostate hyperplasia: 12-month safety and efficacy results for glands larger than 80 mL. Lasers Med Sci. 2015;30(1):317–323.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Rosen RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. Clin Interv Aging. 2008;3(3):511–524.
   PubMed Web of Science ®Google Scholar
• Lane KS. Using innovative technologies and other conditions of safe use to expand which drug products can be considered nonprescription. Public Hearing. 2012;77:12059.
   Google Scholar
• Fowke JH, Munro H, Signorello LB, et al. Urologic Diseases of America Project. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Int Med. 2011;26(11):1305–1310.
   PubMed Web of Science ®Google Scholar
• Sandman D, Simantov E, An C. Out of touch: American men and the health care system. Commonwealth fund men’s and women’s health survey findings. New York (NY): The Commonwealth Fund; 2000.
   Google Scholar
• Yousaf O, Grunfeld EA, Hunter MS. A systematic review of the factors associated with delays in medical and psychological help-seeking among men. Health Psychol Rev. 2015;9(2):264–276.
   PubMed Web of Science ®Google Scholar
• Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49(6):616–623.
   PubMed Web of Science ®Google Scholar
• Tedstone Doherty D, Kartalova‐O’Doherty Y. Gender and self‐reported mental health problems: predictors of help seeking from a general practitioner. Br J Health Psychol. 2010;15(1):213–228.
   PubMedGoogle Scholar
• Roehrborn CG, Lowe FC, Gittelman M, et al. Feasibility of an alternative option for the management of male lower urinary tract symptoms. J Urol. 2016;195(1):125–130.
   PubMed Web of Science ®Google Scholar
• Shaw C, Tansey R, Jackson C, et al. Barriers to help seeking in people with urinary symptoms. Fam Pract. 2001;18(1):48–52.
   PubMed Web of Science ®Google Scholar
• Hall SA, Link CL, Hu JC, et al. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU Int. 2009;104(11):1680–1688.
   PubMed Web of Science ®Google Scholar
• Wallner LP, Slezak JM, Loo RK, et al. Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men’s Health Study. BJU Int. 2015;115(1):127–133.
   PubMed Web of Science ®Google Scholar
• Kirby W, Ferguson J, Johnson D, et al. Future supply of urologists: projected to decrease dramatically between 2009-2025. J Urol. 2013;189(4 suppl):e171–e172.
   PubMed Web of Science ®Google Scholar
• Williams TEJ, Satiani B, Thomas A, et al. The impending shortage and the estimated cost of training the future surgical workforce. Ann Surg. 2009;250(4):590–597.
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. Drug applications for over-the-counter (OTC) drugs. 2015. [2017 Nov 6]. Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/over-the-counterdrugs/default.htm.
   Google Scholar
• Enlarged prostate: what treatments are there? BMJ Best Practice. 2016. [2017 Nov 6]. Available from: http://bestpractice.bmj.com/best-practice/pdf/patient-summaries/532190.pdf.
   Google Scholar
• Lukacs B, Cornu JN, Aout M, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. Eur Urol. 2013;64(3):493–501.
   PubMed Web of Science ®Google Scholar
• Hutchison A, Farmer R, Verhamme K, et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol. 2007;51(1):207–215.
   PubMed Web of Science ®Google Scholar
• Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001423.
   PubMedGoogle Scholar
• Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001423.
   PubMed Web of Science ®Google Scholar
• Ma CH, Lin WL, Lui SL, et al. Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials. Asian J Androl. 2013;15(4):471–482.
   PubMed Web of Science ®Google Scholar
• MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012;109(12):1756–1761.
   PubMed Web of Science ®Google Scholar
• Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557–566.
   PubMed Web of Science ®Google Scholar
• Ilic D, Misso M. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas. 2012;72(4):269–276.
   PubMed Web of Science ®Google Scholar
• Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12:CD001423.
   PubMedGoogle Scholar
• Russo A, Capogrosso P, La Croce G, et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf. 2016;15(12):1611–1670.
   Web of Science ®Google Scholar
• Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344–1351.
   PubMed Web of Science ®Google Scholar
• Curtis P, Gaylord S. Safety issues in the interaction of conventional, complementary, and alternative health care. Complement Health Pract Rev. 2005;10(1):3–31.
   Google Scholar
• Yuan J, Liu Y, Yang Z, et al. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin. 2013;29(3):279–287.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Gratzke C, McVary KT, et al. Are over-the-counter alpha-blockers in the best interest of men with lower urinary tract symptoms? Urol Pract. 2017;4(5):395–404.
   Google Scholar
• OTC tamsulosin for benign prostatic hyperplasia. Drug Ther Bull. 2010;48(10):113–116.
   PubMedGoogle Scholar
• Bechis SK, Otsetov AG, Ge R, et al. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 2014;192(1):16–23.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Prescription to over-the-counter (OTC) switch list. 2017. [2017 Nov 6]. Available from: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm106378.htm
   Google Scholar
• Consumer Healthcare Products Association. The value of OTC medicine to the United States. 2012.
   Google Scholar
• Boardman HF, Heeley G. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors. Int J Clin Pharm. 2015;37(5):709–716.
   PubMed Web of Science ®Google Scholar